Shares of AstraZeneca PLC AZN inched up 0.05% to £110.46 Thursday, on what proved to be an all-around positive trading ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

AstraZeneca PLC AZN shares inched down 0.11% to £110.40 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.04% to 8,545.13.

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...